Cargando…

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real-world data and direct comparisons are scarce. This real-life study explored the safety profile of pirfenidone an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levra, Stefano, Guida, Giuseppe, Sprio, Andrea Elio, Crosa, Flavio, Ghio, Paolo Carlo, Bertolini, Francesca, Carriero, Vitina, Albera, Carlo, Ricciardolo, Fabio Luigi Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775369/ https://www.ncbi.nlm.nih.gov/pubmed/36551989 http://dx.doi.org/10.3390/biomedicines10123229

Ejemplares similares

Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes
por: Guida, Giuseppe, et al.
Publicado: (2023)

Clinical Characterization of the Frequent Exacerbator Phenotype in Asthma
por: Sprio, Andrea Elio, et al.
Publicado: (2020)

Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Phenotype overlap in the natural history of asthma
por: Ricciardolo, Fabio L.M., et al.
Publicado: (2023)

Which Therapy for Non-Type(T)2/T2-Low Asthma
por: Ricciardolo, Fabio L. M., et al.
Publicado: (2021)

Bone Morphogenic Proteins and Their Antagonists in the Lower Airways of Stable COPD Patients
por: Di Stefano, Antonino, et al.
Publicado: (2023)

MicroRNAs as Biomarkers in Corticosteroid-Resistant/Neutrophilic Asthma: Still a Long Way to Go!
por: Ricciardolo, Fabio L. M., et al.
Publicado: (2020)

Critical evaluation of asthma biomarkers in clinical practice
por: Guida, Giuseppe, et al.
Publicado: (2022)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
por: Kolonics-Farkas, Abigél M., et al.
Publicado: (2020)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Pragmatic Markers in the Management of Asthma: A Real-World-Based Approach
por: Ciprandi, Giorgio, et al.
Publicado: (2020)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
por: Biondini, Davide, et al.
Publicado: (2021)

Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients
por: Bondue, Benjamin, et al.
Publicado: (2019)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease
por: Di Stefano, Antonino, et al.
Publicado: (2022)

Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification
por: Palermo, Monica, et al.
Publicado: (2021)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly
por: Honda, Kojiro, et al.
Publicado: (2023)

Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study
por: Poletti, V., et al.
Publicado: (2021)

Antifibrotics in India
por: Dhar, Raja
Publicado: (2019)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
por: Noor, Saba, et al.
Publicado: (2020)

Evaluation of Innate Immune Mediators Related to Respiratory Viruses in the Lung of Stable COPD Patients
por: D’Anna, Silvestro E., et al.
Publicado: (2020)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

The Elusive Antifibrotic Macrophage
por: Adhyatmika, Adhyatmika, et al.
Publicado: (2015)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail, Mona H, et al.
Publicado: (2011)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
por: Raman, Lavanya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kkoufmpfk3cuesr7rjk426hlaa